Previous 10 | Next 10 |
2023-07-27 11:49:43 ET Gossamer Bio ( NASDAQ: GOSS ) fell ~4% Thursday noon after UBS downgraded the biopharmaceutical company, having said the next few years are more about execution. The ratings agency lowered the recommendation on the company to Neutral from Buy, and d...
- Call will be held on Tuesday, July 25 th beginning at 10 a.m. EDT - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced t...
2023-07-20 08:33:09 ET Biopharmaceutical company Gossamer Bio ( NASDAQ: GOSS ) said on Thursday that it is set to offer securities in an ~$212M private placement. The company has entered into a securities purchase agreement with institutional and accredited investors. Goss...
2023-07-20 08:29:22 ET Netcapital NCPL -42% on $1.2M equity offering . Gossamer Bio ( GOSS ) -21% announces $212 Million private placement financing . DURECT Corporation ( DRRX ) -19% announces $15 Million Registered Direct Offering . Jianzhi Ed...
- In Conjunction with Offering, Interim TORREY OLE Data and PROSERA Phase 3 Design Disclosed via 8-K; Conference Call to Discuss Data and Phase 3 Design with Leading PAH KOLs to be Held on July 25 th - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company foc...
2023-06-14 10:03:06 ET Gainers: Inventiva ( IVA ) +25% . Gossamer Bio ( GOSS ) +21% . Akoya Biosciences ( AKYA ) +19% . InVivo Therapeutics ( NVIV ) +14% . Bone Biologics ( BBLG ) +13% . Losers: IO Biotech ( IOBT ...
2023-06-14 08:32:59 ET IO Biotech ( IOBT ) +33% Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone. WiSA Technologies ( WISA ) +36% . Inventiva ( IVA ) +35% announces positive topline results from the investigator-initia...
2023-05-20 10:30:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be ...
News, Short Squeeze, Breakout and More Instantly...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement ...
2024-05-06 14:15:02 ET H.C. Wainwright analyst issues BUY recommendation for GOSS on May 6, 2024 11:58AM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.7499 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...